<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Altum Sequencing]]></title><description><![CDATA[Altum Sequencing]]></description><link>https://www.altumsequencing.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Tue, 16 Jun 2026 08:01:15 GMT</lastBuildDate><atom:link href="https://www.altumsequencing.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[South Summit 2026 – Winner Health Vertical]]></title><description><![CDATA[Selected as a winner in the Health Vertical at South Summit Madrid, one of the world's leading startup conferences. Chosen from thousands of global applicants, this recognition highlights the company's excellence in biotechnology and its role as a key innovator in the future of healthcare and precision medicine.]]></description><link>https://www.altumsequencing.com/post/south-summit-2026-winner-health-vertical</link><guid isPermaLink="false">6a2810855b452722a3b5afa6</guid><pubDate>Tue, 09 Jun 2026 13:11:12 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_1f00a4f9073142a4bfded9800b8e0258~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Identification of minimal residual disease using the TRACKseq (CloneSight) test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer ]]></title><description><![CDATA[This prospective exploratory study evaluated a tumor-informed ctDNA assay for MRD detection in HR+ early breast cancer, showing potential for anticipating late relapse before clinical recurrence. ]]></description><link>https://www.altumsequencing.com/post/identification-of-minimal-residual-disease-using-the-clonesight-test-for-ultrasensitive-ctdna-detect</link><guid isPermaLink="false">6a21d8c1e3c740ba363750c2</guid><pubDate>Thu, 04 Jun 2026 19:59:20 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_4e582f28c46b44929498d250c4626283~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges ]]></title><description><![CDATA[This study evaluated liquid biopsy-based MRD monitoring in AML using cfDNA and NGS, highlighting both its potential and the technical challenges that remain. ]]></description><link>https://www.altumsequencing.com/post/detection-of-minimal-residual-disease-in-acute-myeloid-leukemia-evaluating-utility-and-challenges</link><guid isPermaLink="false">6a21d829367ed35011d61a5e</guid><pubDate>Thu, 04 Jun 2026 19:56:46 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_d9b51f7cfdf84c2f886cd478e7bef383~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease ]]></title><description><![CDATA[This study showed that cfDNA genetic profiling from liquid biopsy can complement tissue biopsy for B-cell lymphoma diagnosis and PET/CT for MRD surveillance. ]]></description><link>https://www.altumsequencing.com/post/genetic-profiling-of-cell-free-dna-in-liquid-biopsies-a-complementary-tool-for-the-diagnosis-of-b-c</link><guid isPermaLink="false">6a21d78a1f44c606b37521d1</guid><pubDate>Thu, 04 Jun 2026 19:54:24 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/0948c3b4e6c343f389f1be806504bb15.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients ]]></title><description><![CDATA[This proof-of-principle study explored personalized ctDNA monitoring after CAR-T therapy in follicular lymphoma, showing potential value for response assessment and post-treatment surveillance. ]]></description><link>https://www.altumsequencing.com/post/personalized-monitoring-of-circulating-tumor-dna-with-a-specific-signature-of-trackable-mutations-af</link><guid isPermaLink="false">6a21d701367ed35011d617c4</guid><pubDate>Thu, 04 Jun 2026 19:51:42 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/5e937ac9c1d942b696c30c38a4cc06eb.jpg/v1/fit/w_1000,h_908,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT ]]></title><description><![CDATA[This real-life follicular lymphoma study showed that liquid biopsy MRD monitoring by ultra-deep sequencing complements PET/CT and helps identify patients at higher risk of progression. ]]></description><link>https://www.altumsequencing.com/post/real-life-disease-monitoring-in-follicular-lymphoma-patients-using-liquid-biopsy-ultra-deep-sequenci</link><guid isPermaLink="false">6a21d65e14f1bdc71962894f</guid><pubDate>Thu, 04 Jun 2026 19:49:21 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/217ca1d0ae8c4ae696caa30387872a4b.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA ]]></title><description><![CDATA[This study developed a DNA-based ultra-deep NGS method to detect BCR::ABL1 kinase domain mutations in CML and Ph+ ALL, supporting sensitive monitoring of therapy resistance. ]]></description><link>https://www.altumsequencing.com/post/detection-of-kinase-domain-mutations-in-bcr-abl1-leukemia-by-ultra-deep-sequencing-of-genomic-dna</link><guid isPermaLink="false">6a21d593513f7725cf1fa0ea</guid><pubDate>Thu, 04 Jun 2026 19:46:09 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c22a133631fe4bd097252f75db1e8422.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia ]]></title><description><![CDATA[This study validated a deep targeted sequencing method for AML MRD monitoring, showing that sequencing-determined MRD positivity was associated with inferior disease-free and overall survival. ]]></description><link>https://www.altumsequencing.com/post/a-novel-deep-targeted-sequencing-method-for-minimal-residual-disease-monitoring-in-acute-myeloid-leu</link><guid isPermaLink="false">6a21902b56a1da0d44a30277</guid><pubDate>Thu, 04 Jun 2026 14:49:33 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_f0c6f8e707504393818b7e76b1d1c45f~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma ]]></title><description><![CDATA[This work analytically and clinically validated an in-house deep-sequencing workflow for MRD monitoring in multiple myeloma, demonstrating high applicability, sensitivity and prognostic value. ]]></description><link>https://www.altumsequencing.com/post/analytical-and-clinical-validation-of-a-novel-in-house-deep-sequencing-method-for-minimal-residual-d</link><guid isPermaLink="false">6a218f911f44c606b3747cea</guid><pubDate>Thu, 04 Jun 2026 14:47:09 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/0e851514ec6b4c868c40c8bd02808147.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. ]]></title><description><![CDATA[This study established the prognostic value of deep sequencing-based MRD detection in multiple myeloma, showing that MRD negativity identifies patients with longer time to progression and overall survival. ]]></description><link>https://www.altumsequencing.com/post/prognostic-value-of-deep-sequencing-method-for-minimal-residual-disease-detection-in-multiple-myelom</link><guid isPermaLink="false">6a218ea156a1da0d44a2fedc</guid><pubDate>Thu, 04 Jun 2026 14:43:55 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_6a8203f6dba94f62ba5a6d430465f18f~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[First Award VI Edition “Open Call for Deep Tech Startups” Foro Transfiere(Málaga) – 26/02/2026]]></title><description><![CDATA[Awarded first place in the prestigious Deep Tech startup competition at Foro Transfiere, Spain’s leading R&#38;D and Knowledge Transfer forum. This top honor recognizes the company’s disruptive technological potential and its excellence in transferring high-impact scientific research to the global market.]]></description><link>https://www.altumsequencing.com/post/first-award-vi-edition-open-call-for-deep-tech-startups-foro-transfiere-m%C3%A1laga-26-02-2026</link><guid isPermaLink="false">6a21841e1f44c606b37463b2</guid><pubDate>Thu, 04 Jun 2026 13:57:52 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_781901f1c8a941d2b72a95744c0526bd~mv2.jpeg/v1/fit/w_800,h_600,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Finalists at the RETECH Innovation Forum (Madrid) – 27/02/2026]]></title><description><![CDATA[Selected as a finalist in the RETECH Innovation Forum, a key event within the "Redes de Emprendimiento Digital" national framework. This recognition highlights the project’s strategic value in the digital transformation of the healthcare sector through the integration of advanced data and AI solutions.]]></description><link>https://www.altumsequencing.com/post/finalists-at-the-retech-innovation-forum-madrid-27-02-2026</link><guid isPermaLink="false">6a2183e0513f7725cf1ee636</guid><pubDate>Thu, 04 Jun 2026 13:56:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_2e0375767e3244c992cd07c65204f451~mv2.jpeg/v1/fit/w_275,h_183,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Finalist in the AstraZeneca ACCIÓN Program for Startups, Health Cluster(Madrid) – 04/02/2026]]></title><description><![CDATA[Named a finalist in AstraZeneca’s flagship acceleration program, "ACCIÓN," in collaboration with the regional Health Cluster. This selection underscores the company’s clinical relevance and its potential to establish strategic partnerships with the pharmaceutical industry to improve cancer patient outcomes.]]></description><link>https://www.altumsequencing.com/post/finalist-in-the-astrazeneca-acci%C3%B3n-program-for-startups-health-cluster-madrid-04-02-2026</link><guid isPermaLink="false">6a218396367ed35011d5592e</guid><pubDate>Thu, 04 Jun 2026 13:55:17 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_48d664124f0040bebe323cfbe9541ca7~mv2.jpg/v1/fit/w_1000,h_682,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Top 10 Scaleups Santander X]]></title><description><![CDATA[A prestigious national recognition by Banco Santander that identifies the most promising high-growth companies in Spain. As a Top 10 Scaleup, the company was selected for its innovative business model, scalability, and potential to lead the digital transformation within the Spanish entrepreneurial ecosystem.]]></description><link>https://www.altumsequencing.com/post/top-10-scaleups-santander-x</link><guid isPermaLink="false">6a21834ae3c740ba36368ca7</guid><pubDate>Thu, 04 Jun 2026 13:54:08 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_0b164e4d900644b1a7db0bbf121d761e~mv2.jpeg/v1/fit/w_275,h_183,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Top 10 Scaleups VDS]]></title><description><![CDATA[Selected from over 1,200 candidates across 84 countries, the company was named one of the Top 10 finalists in the Valencia Digital Summit (VDS) international competition. This recognition highlights the project’s disruptive nature and its ability to address global challenges through advanced technology and scientific innovation.]]></description><link>https://www.altumsequencing.com/post/top-10-scaleups-vds</link><guid isPermaLink="false">6a21831d513f7725cf1ee461</guid><pubDate>Thu, 04 Jun 2026 13:52:53 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_3d880a546ec649a18826102df91adc1e~mv2.png/v1/fit/w_1000,h_900,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Finalist in the Santander X Spain Award]]></title><description><![CDATA[National recognition identifying high-potential innovative companies in Spain. As a finalist, the company was selected to represent Spain in the global entrepreneurship stages, highlighting its business scalability and technological impact.]]></description><link>https://www.altumsequencing.com/post/finalist-in-the-santander-x-spain-award</link><guid isPermaLink="false">6a21828daaa8d363bc430abe</guid><pubDate>Thu, 04 Jun 2026 13:50:44 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_eefb4c9133b04d6db347649e6f3eda6d~mv2.jpg/v1/fit/w_1000,h_800,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[Finalist in the Santander X Global Challenge / Reimagine Silver Age]]></title><description><![CDATA[A prestigious international challenge organized by Santander and Philips to find disruptive solutions for healthy aging. The company received an Honorary Mention for its advanced liquid biopsy and AI platform, recognized among 500 participants from 11 countries.]]></description><link>https://www.altumsequencing.com/post/finalist-in-the-santander-x-global-challenge-reimagine-silver-age</link><guid isPermaLink="false">6a21824e367ed35011d555f2</guid><pubDate>Thu, 04 Jun 2026 13:49:43 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_1d99e8baf9e7492cbc81c9714925f236~mv2.jpeg/v1/fit/w_800,h_418,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[“Revista Emprendedores”: Top 50 Most innovative Spanish Startups 2024]]></title><description><![CDATA[Selected by Emprendedores magazine as one of the 50 most innovative startups in Spain for 2024. This prestigious annual list recognizes companies with the highest disruptive potential, highlighting our advanced AI and genomic sequencing platform as a benchmark in the Spanish deep-tech and healthcare landscape.]]></description><link>https://www.altumsequencing.com/post/revista-emprendedores-top-50-most-innovative-spanish-startups-2024</link><guid isPermaLink="false">6a21820c14f1bdc71961c78f</guid><pubDate>Thu, 04 Jun 2026 13:48:37 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_8ae308cbb18f417688fa0e8a9d6319ae~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[APTE: Top 100 Best Startups of 2024]]></title><description><![CDATA[Recognized by the Association of Science and Technology Parks of Spain (APTE) as one of the 100 best startups of 2024. This selection highlights the company’s high degree of innovation and its impact within the national technological ecosystem, featuring Altum Sequencing as a leader in scientific excellence and deep-tech development.]]></description><link>https://www.altumsequencing.com/post/apte-top-100-best-startups-of-2024</link><guid isPermaLink="false">6a2181c7de6a4fa1b1f24679</guid><pubDate>Thu, 04 Jun 2026 13:47:30 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_54621d9a8f234d808fffe7bc32bb5bf7~mv2.png/v1/fit/w_1000,h_576,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item><item><title><![CDATA[UNELE – XIII City of Leganés Business Award: Best Business Initiative]]></title><description><![CDATA[Awarded for the Best Business Initiative by the Leganés Business Union (UNELE) during the XIII edition of the City of Leganés Business Awards. This recognition celebrates the company’s technological excellence and its strategic contribution to the local and regional innovation ecosystem as a leading deep-tech firm.]]></description><link>https://www.altumsequencing.com/post/unele-xiii-city-of-legan%C3%A9s-business-award-best-business-initiative</link><guid isPermaLink="false">6a218170e3c740ba363687e8</guid><pubDate>Thu, 04 Jun 2026 13:46:24 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/396983_47b0a03b123f4689ad406a0cb7fd4ba7~mv2.jpeg/v1/fit/w_800,h_600,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Altum Sequencing</dc:creator></item></channel></rss>